Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD.

Autor: Çolak A; Department of Biochemistry, Tepecik Training and Resesarh Hospital, İzmir, Turkey., Yılmaz C; Chest Diseases Department, Dr. Suat Seren Chest Diseases and Thoracic Surgery Education and Research Hospital, İzmir, Turkey., Toprak B; Department of Biochemistry, Silopi State Hospital, Silopi, Turkey., Aktoğu S; Chest Diseases Department, Dr. Suat Seren Chest Diseases and Thoracic Surgery Education and Research Hospital, İzmir, Turkey.
Jazyk: angličtina
Zdroj: Journal of medical biochemistry [J Med Biochem] 2017 Apr 22; Vol. 36 (2), pp. 122-126. Date of Electronic Publication: 2017 Apr 22 (Print Publication: 2017).
DOI: 10.1515/jomb-2017-0011
Abstrakt: Background: Serum procalcitonin (PCT) and C-reactive protein (CRP) are markers of systemic inflammation and bacterial infection. We aimed to compare the usefulness of procalcitonin and CRP in patients with community-acquired pneumonia and exacerbations of chronic obstructive pulmonary disease (COPD).
Methods: A total of 116 consecutive patients were included in the study: 76 with chronic obstructive pulmonary disease in group 1, and 40 with pneumonia in group 2.
Results: Median serum CRP level was 44 mg/L in the COPD group and 132 mg/L in the pneumonia group. Median value of serum PCT was found to be 0.07 in the COPD group and 0.14 ng/mL in the pneumonia group. Serum PCT and CRP levels were significantly higher in the pneumonia group compared to the COPD group (p<0.001). The area under the ROC curve was 0.788 (CI: 0.704-0.872) for CRP and 0.699 (CI: 0.599-0.800) for procalcitonin to identify pneumonia.
Conclusions: Procalcitonin and CRP levels were significantly higher in patients with community-acquired pneumonia presenting to the emergency department with indications for hospitalization than in patients with exacerbations of chronic obstructive pulmonary disease. Serum CRP and procalcitonin concentrations were strongly correlated. CRP might be a more valuable marker in these patients with lower respiratory tract infections.
Competing Interests: Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.
Databáze: MEDLINE
Externí odkaz: